Table 3.

Clinicopathologic characteristics of study participants stratified according to methylation status across 13 CpG loci

Low-methylation (N = 30)Intermediate-methylation (N = 30)High-methylation (N = 31)P
Age at diagnosis, y0.87e
 Range32–8441–8734–80
 Mean (SD)58 (11.1)63 (13.5)59.5 (12.7)
Gender, n (%)0.22f
 Female6 (20)11 (37)6 (19)
 Male24 (80)19 (63)25 (81)
HPV16 status, n (%)0.30f
 Positive8 (27)11 (37)6 (19)
 Negative22 (73)19 (63)25 (81)
Tumor site, n (%)a0.45f
 Oral12 (46)17 (65)17 (71)
 Pharynx7 (27)5 (19)3 (12)
 Larynx7 (27)4 (15)4 (17)
Tumor stage, n (%)b0.71f
 I0 (0)0 (0)2 (7)
 II8 (30)5 (19)8 (29)
 III5 (19)4 (15)4 (14)
 IV14 (52)18 (67)14 (50)
Lifetime drink-years of consumption, nc0.84e
 Range0–510–580–58
 Mean (SD)27 (19)22 (21.7)29 (19)
 Never-drinkers, n545
Lifetime pack-years smoked, nd0.32e
 Range0–1050–1000–125
 Mean (SD)36 (29)30 (28)29 (31)
 Never-smokers, n567
  • aFifteen samples missing site data.

  • bNine tumors missing stage data.

  • cEighteen patients missing self-reported drinking data.

  • dThirteen patients missing self-reported smoking data.

  • eKruskal–Wallis ANOVA.

  • fPermutation χ2 test.